Molecular profiling of clinical relapse (local or metastatic) has identified a small number of recurrent genetic events only in 20% to 40% of patients with advanced ER+ breast cancer (i.e., ESR1 activating mutations; refs. 14–16). Here, ESR1 is linked to breast carcinoma.